In the past, people have accepted that it usually takes about ten years to get a vaccine on the market. Careful testing with proof of success is required for a preparation to receive approvals. Since COVID-19, the pressure to develop has increased dramatically and also the potential to close a lucrative deal, because a lot is at stake for politics and economy. The necessary tests are carried out at great expense in order not to endanger human life through a vaccination, but to protect it. There are great opportunities for investors.
COVID-19 product before market launch
Valeo Pharma (CSE: VPH) is a Canadian pharmaceutical company that claims to manufacture specialty pharmaceuticals and focuses on marketing innovative prescription products in its home country. Valeo Pharma primarily manufactures products for neurodegenerative diseases, oncology products and specialty products for hospitals. The company also has all the required capabilities and the full infrastructure to
register and properly manage its growing product portfolio through all stages of commercialization.
Last week, the company released
information about the launch of Hesperco in Canada. The product was developed by Ingenew Pharma and will be marketed by Valeo Pharma. Ingenew is a biopharmaceutical company focused on addressing unmet medical needs and serving patients and families affected by serious and debilitating illness. Its primary therapeutic areas of interest include oncology, neurology, urology and dermatology.
Hesperco is a trademark of Ingenew Pharma and will be used by Valeo Pharma under a license agreement. Commenting on the partnership with Valeo, Pierre Laurin, CEO of Ingenew, said: "There is a strong scientific and medical rationale for the use of
Hesperco capsules to support the immune system and potentially fight off symptoms associated with Corona viruses such as the one that causes COVID-19. Thousands of compounds have been evaluated since the start of the pandemic and the active compound in Hesperco capsules has been repeatedly reported to be one of the best candidates to interfere with the mechanisms SARS-CoV-2 uses to infect our cells. (…)"
The Valeo team is obviously ready to market the product as soon as possible. "Pending Health Canada's approval, we are poised to proceed with the commercialization of Hesperco capsules," Valeo Pharma CEO Steve Saviuk recently stated in a press release, and continued: "Ingenew's ongoing expansion of scientific data as well as the development of new clinical data will provide further evidence of Hesperco'sTM effectiveness in providing support for the immune system."
Investors in Valeo Pharma can benefit from the fact that the company's market capitalization is still well below EUR 100 million and that its potential is correspondingly high, mainly because the company does not take costly research risks but focuses on the commercialization of successful products.
Sustainable success for the post-Corona era
BioNTech (NASDAQ: BNTX) from Germany has been in the focus of investors since the beginning of the Corona Pandemic because the company's researchers are excellently positioned to research a vaccine. It is therefore not surprising that the share has been actively traded in recent months and that the market capitalization is already in the double-digit billion range.
The business with the COVID-19 vaccine will certainly also have an impact on other research areas of the company and establish new standards in the fight against cancer in the wake of the Corona Pandemic.
Stock market launch thanks to COVID-19
CureVac (NASDAQ: CVAC) is also a German company that has made it to the world stage of the pharmaceutical industry in recent months thanks to COVID-19. The company's market value skyrocketed after the company went public. In the race for a vaccine against the Corona virus, investors may be investing according to the watering can principle in order to be among the winners. The term winner in the context of a deadly Pandemic sounds bizarre,
but ultimately COVID-19 is currently making the industry faster and more efficient and bringing new stars like CureVac to the scene.
CONFLICT OF INTEREST & RISK NOTE
We would like to point out that Apaton Finance GmbH, the owner of news.financial, as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Further details can be found in our ´
Conflict of Interest & Risk Disclosure´.